U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
Go back to U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 58.87 +0.47 (0.80%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.40 | 52 Week High | $108.96 | |||
| Open | $57.99 | 52 Week Low | $62.12 | |||
| Day High | $59.07 | P/E | N/A | |||
| Day Low | $57.42 | EPS | $-1.27 | |||
| Volume | 2,503,782 | |||||
